Triamcinolone
Clinical data | |
---|---|
Trade names | Kenalog, Nasacort, Adcortyl, others |
Other names | Click show to see
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; (1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601122 |
License data | |
Pregnancy category |
|
intra-articular, intra-synovial | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | >90%[4] |
Protein binding | 68%[citation needed] |
Metabolism | Liver[4] |
Onset of action | (2–)24(–48) hours[4][5] |
Elimination half-life | 200–300 minutes (plasma), up to 36 hours (total)[4] |
Excretion | Urine (75%) and faeces (25%)[5] |
Identifiers | |
| |
JSmol) | |
Specific rotation | +65° to +72° |
Melting point | 260 to 271 °C (500 to 520 °F) |
Solubility in water | 2 |
| |
| |
(what is this?) (verify) |
Triamcinolone is a
Common side effects with long-term use include
Triamcinolone was patented in 1956 and came into medical use in 1958.
Medical uses
Triamcinolone is used to treat a number of different medical conditions, such as
The
Contraindications
Contraindications for
There are no contraindications for use in emergency medicine.[4]
Side effects
Side effects of triamcinolone are similar to other corticoids. In short-term treatment up to ten days, it has very few adverse effects; however, sometimes
Side effects of triamcinolone long-term treatment may include coughing (up to
Overdose
No acute overdosing of triamcinolone has been described.[17]
Interactions
- Atropine and other anticholinergics can substantially increase pressure in the eyes.
- Antidiabetic drugscan become less effective because triamcinolone causes diabetes-like symptoms.
- anticoagulants such as warfarin, add to the risk of gastrointestinal bleeding.
- Diuretics that excrete potassium (such as loop diuretics and thiazides) can increase the risk of hypokalemia and thus lead to abnormal heart rhythm.
- Cardiac glycosides may have more adverse effects due to reduced potassium levels in the blood.
- The risk for blood count changes is increased when combining triamcinolone with ACE inhibitors.
Triamcinolone and other drugs can also influence each other's concentrations in the body, amounting to pharmacokinetic interactions such as:[4][17]
- Rifampicin, phenytoin, carbamazepine and other inducers of the liver enzyme CYP3A4[19] speed up metabolization of triamcinolone and can therefore reduce its effectiveness.
- Conversely, CYP3A4 inhibitors such as ketoconazole and itraconazole can increase its concentrations in the body and the risk for adverse effects.
- Blood concentrations of ciclosporin can be increased.
Pharmacology
Mechanism of action
Triamcinolone is a glucocorticoid that is about five times as potent as cortisol, but has very little mineralocorticoid effects.[4]
Pharmacokinetics
When taken by mouth, the drug's
A small fraction of the substance is metabolized to 6-hydroxy- and 20-dihydro-triamcinolone; most of it probably undergoes glucuronidation, and a smaller part sulfation. Three quarters are excreted via the urine, and the rest via the faeces.[4][17]
Due to corticoids' mechanism of action, the effects are delayed as compared to plasma concentrations. Depending on the route of administration and the treated condition, the onset of action can be from two hours up to one or two days after application; and the drug can act much longer than its elimination half-life would suggest.[4][5]
Chemistry
Triamcinolone is a
The substance is a light-sensitive, white to off-white, crystalline powder, or has the form of colourless, matted crystals. It has no odour or is nearly odourless. Information on the melting point varies, partly due to the substance's
Society and culture
In 2010, Teva and Perrigo launched the first generic inhalable triamcinolone.[22]
According to Chang et al. (2014), "Triamcinolone acetonide (TA) is classified as an S9 glucocorticoid in the 2014 Prohibited List published by the World Anti-Doping Agency, which caused it to be prohibited in international athletic competition when administered orally, intravenously, intramuscularly or rectally".[23]
References
- ^ "Kenalog Intra-articular / Intramuscular Injection - Summary of Product Characteristics (SmPC)". (emc). 10 June 2020. Retrieved 20 August 2020.
- ^ "Nasacort Allergy 55 micrograms/dose Nasal Spray suspension - Summary of Product Characteristics (SmPC)". (emc). 30 August 2018. Retrieved 20 August 2020.
- ^ "Adcortyl Intra-Articular/Intradermal Injection 10mg/ml - Summary of Product Characteristics (SmPC)". (emc). 11 December 2017. Retrieved 20 August 2020.
- ^ ISBN 978-3-7741-9846-3.
- ^ a b c d e f Triamcinolone (systemic) Professional Drug Facts. Accessed 19 August 2020.
- ^ a b c d e f g "Triamcinolone Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "Triamcinolone Use During Pregnancy". Drugs.com. Retrieved 3 March 2019.
- ISBN 978-3-527-60749-5.
- ISBN 978-0-8036-7000-6.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Triamcinolone - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ "Triamcinolone: Uses, Dosage, Side Effects, Warnings". Drugs.com.
- ^ "Azmacort Inhaler: Side Effects, Dosage & Uses". Drugs.com.
- ^ "Alcon Receives FDA Approval of Triesence Injectable Triamcinolone Suspension for Use in Eye Surgery". Drugs.com.
- S2CID 44337035.
- PMID 24813302.
Topical corticosteroids (TCS) are used in the management of AD in both adults and children and are the mainstay of anti-inflammatory therapy.
- ^ a b c d e f g Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Volon 4 mg-Tabletten.
- ^ "Drugs and Treatments – Nasacort AQ Nasl – Patient Handout". WebMD. Retrieved 24 March 2008.
- PMID 23143891.
- ISBN 978-1-4757-2085-3.
- ISBN 978-3-88763-075-1.
- ^ "Perrigo Announces Launch Of Generic Version Of Nasacort AQ". 15 June 2011.
- PMID 25126738.
External links
- "Triamcinolone Topical". MedlinePlus.
- "Triamcinolone Nasal Spray". MedlinePlus.